Sacubitril/valsartan reduces levels of procollagen types I and III and correlates with reverse cardiac remodeling
| Autor: | Álvaro Herrera-Escandón, Ángela M. Rodríguez-Casanova, Carlos A. Plata-Mosquera, Laura P. Uribe-Posso, Wikler Bernal-Torres, Anyi C. Puerta-Mesa, Maria Eugenia Casanova-Valderrama, Marcela Vivas-Mayor, Jazmín Martínez-Aristizabal |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Ejection fraction Ischemic cardiomyopathy business.industry medicine.disease Sacubitril Procollagen peptidase Valsartan Internal medicine Heart failure Idiopathic dilated cardiomyopathy medicine Cardiology Cardiology and Cardiovascular Medicine business Sacubitril Valsartan medicine.drug |
| Zdroj: | REC: CardioClinics. 56:14-21 |
| ISSN: | 2605-1532 |
| DOI: | 10.1016/j.rccl.2020.06.002 |
| Popis: | Introduction and objectives Extracellular matrix turnover is a major determinant of cardiac remodeling in heart failure. Sacubitril/valsartan decreases serum levels of procollagen type I amino-terminal peptide (PINP) and procollagen type III amino-terminal peptide (PIIINP), but its correlation with reverse remodeling is unknown. The purpose of this study is to determine the effect of sacubitril/valsartan on the profibrotic PINP and PIIINP biomarkers and their association with reverse cardiac remodeling in patients with heart failure with reduced ejection fraction (HFrEF). Methods Prospective, single-center, open-label study of 401 outpatients with HFrEF initiated with sacubitril/valsartan treatment according to Guideline-Directed Medical Therapy. Change in serum levels of PINP, PIIINP, left ventricle end-diastolic volume index, left ventricle end-systolic volume index and left ventricle ejection fraction were analyzed from baseline to 12-month follow-up. Results Baseline levels of PINP and PIIINP were highest (above-median) in 63 patients with ischemic cardiomyopathy and 19 with idiopathic dilated cardiomyopathy, decreasing −36 μg/L for PINP (95%CI, 78–93; P Conclusions These findings suggest that changes in fibrosis markers induced by sacubitril-valsartan therapy in HFrEF are related to reverse cardiac remodeling in patients with higher PINP and PIIINP levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|